Combined Drug-Radiation Treatment: Biological Basis, Current Applications and Perspectives

Seoul, South Korea

[ Radiotherapy ]
[ Chemotherapy ]

The course is aimed at radiation oncologists and medical oncologists involved in the multidisciplinary treatment of cancer.

Course director 

  • Barbara Jereczek-Fossa, Radiation Oncologist and Clinical Oncologist, European Institute of Oncology and University of Milan, Milan (IT)

Teachers 

  • Giuseppe Curigliano, Medical Oncologist, European Institute of Oncology, Milan (IT) 

  • Rob Glynne-Jones, Radiation Oncologist, Mount Vernon Centre for Cancer Treatment, London (UK) 

  • Jesper Grau Eriksen, Clinical Oncologist, Odense University Hospital, Odense (DK)

  • Mario Levis, Radiation Oncologist, University of Turin, Turin (IT)  

  • Martin Pruschy, Biologist, University Hospital Zürich, Zürich (CH) 

  • Li Tee Tan, Consultant Oncologist, Cambridge University Hospital, NHS Trust, Cambridge (UK)

Local Organiser 

  • Sung Hwan Kim, Radiation Oncologist, The Catholic University of Korea

Effective cancer treatment necessitates both high efficacy of local treatment and combatting sub-clinical systemic disease. Consequently, cancer therapy today involves various combinations of local and systemic treatment modalities. Of those, combining drugs and radiation has been attracting particular attention both in terms of its biological rationale and its potential of increasing the therapeutic outcome. The course aims at updating participants about established and emerging knowledge in this field. It will provide the key-messages that biological and clinical research is currently bringing to the oncology community.

This course aims to:

  • Update participants about biological effects of combining drugs and radiation in normal and tumour tissue
  • Present evidence-based clinical applications of combined modality treatment using drugs and radiation in major human malignancies
  • Stimulate case-based discussion on the interdisciplinary treatment of cancer
  • Present future perspectives for combining drugs and radiation.

Learning outcomes

By the end of this course participants should be able to:

  • Describe the rationale and mechanisms of the action of combined drug radiation treat­ment in cancer
  • Discuss the evidence for combined drug ra­diation treatment in different tumour sites
  • Select patients for combined drug radiation treatment
  • Decide on the optimum treatment strategy, sequencing and duration, for different patients
  • Decide on the optimum strategy including new drugs (immunotherapy etc.).

Course content

General lectures

  • Describe the rationale and mechanisms of the action of combined drug radiation treatment in cancer
  • Immunotherapy and personalised cancer therapy
  • Rationale for altered fractionation and combining radiation with systematic therapies
  • Hypoxia: the point of view of biologist and radiation oncologist
  • Immunotherapy and radiotherapy
  • Decision making
  • Endpoints in oncology
  • Radiotherapy and new drugs: what is known and what is not

Site specific lectures including practical case discussions

  • Head and neck cancer
  • Non small cell lung cancer
  • Small cell lung cancer
  • Breast cancer
  • Prostate cancer
  • Bladder cancer
  • Cervical cancer
  • Oesophageal cancer
  • Gastric cancer
  • Rectal cancer
  • Anal canal
  • Pancreas
  • Brain tumours
  • Lymphomas.

Prerequisites

Before commencing this course participants should:

  • Be confident with the basic mechanisms of radiotherapy and systemic treatment in oncology
  • Know the basic principles of management of solid tumours
  • Know different ways of delivering chemotherapy/systemic therapy in combination with radiotherapy.

Teaching methods

  • 20 hours of lectures
  • 5 hours of case discussions
  • Presentation and critical discussion of the available evidence, discussion of clinical cases.

Methods of assessment

  • MCQ
  • Evaluation form.

Programme

The draft programme is available here.

Key words

  • Radiotherapy
  • Chemotherapy
  • Combined modality
  • Multidisciplinary approach
  • Organ preservation
  • Radiosensitisation
  • Immunotherapy.

Accreditation

Application for CME recognition will be submitted to the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS). EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA). Information on the status of the applications can be obtained from the ESTRO office.

Venue

Severance Hospital, Yonsei University 
50-1 Yonsei-ro 
Sinchon-dong, Seodaemun-gu 
Seoul

Maps and Directions

Accommodation

ESTRO and KORSO will not be providing accommodation. We would recommend that participants would use one of the web booking tools to find suitable accommodation for themselves.

Membership

ESTRO members can order products at substantially reduced prices. Please note that in order to benefit from the member price, you must renew your membership for 2019 before registering to the course.To benefit from these member rates, please visit the membership page to become a member or renew your membership BEFORE proceeding with your order.

Fees

 

Early rate

Late rate

In-training members* 450 EUR 625 EUR
Members 600 EUR 725 EUR
Non Members 750 EUR 850 EUR

* Members with specialty RadiationTherapist (RTT) may register at the In Training fee

Early rates are applied up to three months before the starting date of the course. 
Late rates are applied three months before the starting date of the course.

The fee includes the course material, coffees, lunches, and the social event.



Advance registration & payment are required.

On-site registration will not be available.

Since the number of participants is limited, late registrants are advised to contact the ESTRO office before payment, to inquire about availability of places. Access to homework and/or course material will become available upon receipt of full payment.

 

Insurance and cancellation

 

The organiser does not accept liability for individual medical, travel or personal insurance. Participants are strongly advised to take out their own personal insurance policies.   
In case an unforeseen event would force ESTRO to cancel the meeting, the Society will reimburse the participants fully the registration fees. ESTRO will not be responsible for the refund of travel and accommodation costs.

In case of cancellation, full refund of the registration fee minus 15% for administrative costs may be obtained up to three months before the course and 50% of the fee up to one month before the course. No refund will be made if the cancellation request is postmarked less than one month before the start of the course.

Reduced fees

ESTRO members from economically challenged countries may register at a preferential rate of 350 Euro if three conditions are met:

  1. Only ESTRO members for 2019 are eligible (please make sure your 2019 membership is in order before you apply for the reduced fees)
  2. Only one course per person per year can be subsidized by ESTRO
  3. Sponsored candidates are not entitled to reduced fees (the invoicing address has to be the one of the participant)  

Please note: 

  • We can only guarantee a certain number of reduced fees per course
  • Application deadlines are the same as early registration fees (3 months before the course date

List of Economically challenged countries and eligible courses 

Grants

Many of our course participants are able to find full or partial funding from sources available locally. 

For more please go to: GRANTS

Check our other educational activities